Skip to main content

Peer Review reports

From: Irinotecan-containing doublet treatment versus irinotecan monotherapy as second-line choice for advanced gastric cancer

Original Submission
16 Oct 2017 Submitted Original manuscript
26 Oct 2017 Author responded Author comments - Liuting Yang
Resubmission - Version 2
26 Oct 2017 Submitted Manuscript version 2
12 Jan 2018 Reviewed Reviewer Report - Bhavana Bhagya Rao
23 Jan 2018 Reviewed Reviewer Report - Quadri Alabi
21 Feb 2018 Author responded Author comments - Liuting Yang
Resubmission - Version 3
21 Feb 2018 Submitted Manuscript version 3
Publishing
26 Mar 2018 Editorially accepted
2 Apr 2018 Article published 10.1186/s12876-018-0772-4

You can find further information about peer review here.

Back to article page